Prognostic Value of PD-L1 and Siglec-15 Expression in Patients with Nasopharyngeal Carcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jun 21

PMID 35729260

Authors

Ju Zhao

Hanshan Yang

Hui Hu

Chao Liu

Min Wei

Yumei Zhao

Yudan Chen

Yongxia Cui

Ping Chen

Kang Xiong

Yun Lu

Hongru Yang

Linglin Yang

Affiliations

Soon will be listed here.

Abstract

Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) might be involved in the activation of important pathways related to tumor immune escape, along with programmed death-ligand 1 (PD-L1). Here, we aimed to investigate the correlation between the expression of Siglec-15 and PD-L1 in nasopharyngeal carcinoma (NPC) patients. We determined the expression of PD-L1 via immunohistochemical staining and that of Siglec-15 via immunofluorescence staining in 182 NPC tissue samples. A significant correlation was identified between the PD-L1 and Siglec-15 expression (P = 0.000). Moreover, Kaplan-Meier survival curves showed that PD-L1 expression was associated with improved overall survival (OS) (P = 0.025) and Siglec-15 expression was associated with improved distant failure-free survival (D-FFS) (P = 0.048). Moreover, multivariate Cox analysis showed that PD-L1 and Siglec-15 were independent predictors of OS (P = 0.020) and D-FFS (P = 0.047), respectively. The results of the log-rank test and Cox regression analyses showed that patients exhibiting no PD-L1/Siglec-15 expression had significant advantages regarding OS, compared to other groups (P = 0.037). PD-L1 and Siglec-15 may represent novel biomarkers for predicting the prognosis of NPC patients. Siglec-15 may be considered as a potential target for the development of therapeutics for NPC treatment in the future.

Citing Articles

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer.

Chu C, Fu Y, Yang J, Fan X, Shi J Front Oncol. 2025; 14:1437006.

PMID: 39743995 PMC: 11688221. DOI: 10.3389/fonc.2024.1437006.

Expression of SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and breast cancer progression.

Lai H, Liu Y, Gong Y, Zong C, Zeng W, Chen H PLoS One. 2024; 19(11):e0313561.

PMID: 39541298 PMC: 11563486. DOI: 10.1371/journal.pone.0313561.

Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis.

Jiang K, Qi L, Liu X, Wang Y, Wang L Front Oncol. 2023; 12:1073932.

PMID: 36713548 PMC: 9875589. DOI: 10.3389/fonc.2022.1073932.

Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes.

Lu Z, Cheng P, Huang F, Li J, Wang B, Zou S J Pathol Clin Res. 2022; 9(2):121-128.

PMID: 36424637 PMC: 9896156. DOI: 10.1002/cjp2.303.

References

Hao J, Nong J, Zhao D, Li H, Su D, Zhou L . The significance of Siglec-15 expression in resectable non-small cell lung cancer. Neoplasma. 2020; 67(6):1214-1222. DOI: 10.4149/neo_2020_200220N161. View

Wei M, Peng J, Wu P, Chen P, Yang H, Cui Y . Prognostic value of TIGAR and LC3B protein expression in nasopharyngeal carcinoma. Cancer Manag Res. 2018; 10:5605-5616. PMC: 6237137. DOI: 10.2147/CMAR.S175501. View

Lee V, Lo A, Leung C, Shek W, Kwong D, Lam K . Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. PLoS One. 2016; 11(6):e0157969. PMC: 4920427. DOI: 10.1371/journal.pone.0157969. View

Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View

Ren X . Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol Med. 2019; 16(2):205-210. PMC: 6713637. DOI: 10.20892/j.issn.2095-3941.2018.0141. View

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018; 19(10):1338-1350. DOI: 10.1016/S1470-2045(18)30495-9. View

Huang Z, Liu S, Wang G, Zheng S, Ding S, Tao Y . The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int. 2019; 19:141. PMC: 6530183. DOI: 10.1186/s12935-019-0863-5. View

Baptista M, Sarian L, Derchain S, Pinto G, Vassallo J . Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2015; 47(1):78-84. DOI: 10.1016/j.humpath.2015.09.006. View

. Siglec-15: An Attractive Immunotherapy Target. Cancer Discov. 2019; 10(1):7-8. DOI: 10.1158/2159-8290.CD-NB2019-136. View

10.

Kleffel S, Posch C, Barthel S, Mueller H, Schlapbach C, Guenova E . Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015; 162(6):1242-56. PMC: 4700833. DOI: 10.1016/j.cell.2015.08.052. View

11.

Bigras G, Mairs S, Swanson P, Morel D, Lai R, Izevbaye I . Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas. Appl Immunohistochem Mol Morphol. 2018; 26(10):701-708. DOI: 10.1097/PAI.0000000000000698. View

12.

Li Y, Ding J, Liao L, Zhang Z, Liao S, Wu Y . Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol. 2017; 7(3):378-382. PMC: 5530303. DOI: 10.3892/mco.2017.1318. View

13.

Xu F, Xu L, Wang Q, An G, Feng G, Liu F . Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015; 8(9):14595-603. PMC: 4658831. View

14.

Kerr K, Tsao M, Nicholson A, Yatabe Y, Wistuba I, Hirsch F . Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. J Thorac Oncol. 2015; 10(7):985-9. DOI: 10.1097/JTO.0000000000000526. View

15.

Wang G, Ionescu D, Lee C, Hiruki T, Myers R, Shaipanich T . PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. Lung Cancer. 2019; 136:1-5. DOI: 10.1016/j.lungcan.2019.07.033. View

16.

Cao G, Xiao Z, Yin Z . Normalization cancer immunotherapy: blocking Siglec-15!. Signal Transduct Target Ther. 2019; 4:10. PMC: 6473001. DOI: 10.1038/s41392-019-0045-x. View

17.

Liu M, Chen M, Huang C, Huang C . Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development. World J Oncol. 2017; 6(1):243-261. PMC: 5649942. DOI: 10.14740/wjon610w. View

18.

Carreno B, Collins M . The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002; 20:29-53. DOI: 10.1146/annurev.immunol.20.091101.091806. View

19.

Fudaba H, Momii Y, Hirakawa T, Onishi K, Asou D, Matsushita W . Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients. Sci Rep. 2021; 11(1):1206. PMC: 7806611. DOI: 10.1038/s41598-020-79742-9. View

20.

Murugesan G, Correia V, Palma A, Chai W, Li C, Feizi T . Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression. Glycobiology. 2020; 31(1):44-54. PMC: 7799145. DOI: 10.1093/glycob/cwaa048. View